Continuum Advisory’s Janux Therapeutics JANX Stock Holding History

Continuum Advisory’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-47	Closed	-$1.27K	–	1023
2025 Q1	$1.27K	Buy	47 +5	+12%	+$188	﹤0.01%	1468
2024 Q4	$2.25K	Sell	42 -13	-24%	-$688	﹤0.01%	1378
2024 Q3	$2.81K	Buy	55 +6	+12%	+$261	﹤0.01%	1320
2024 Q2	$2.05K	Hold	49	–	–	﹤0.01%	1295
2024 Q1	$2.54K	Buy	+49	New	+$1.07K	﹤0.01%	1233

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Continuum Advisory's JANX Position: Q2 2025 in Review

Continuum Advisory sold out of Janux Therapeutics (JANX) in Q2 2025, closing a stake of 47 shares — an estimated $1.27K sold.

Continuum Advisory first reported a position in JANX in Q1 2024 and held it in 5 quarters. The position peaked at $2.81K in Q3 2024. 174 funds tracked by Wall St. Rank hold JANX as of Q2 2025.

Continuum Advisory reported no remaining Janux Therapeutics position as of Q2 2025 after selling out during the quarter.
Continuum Advisory sold 47 Janux Therapeutics shares in Q2 2025, an estimated $1.27K.
Continuum Advisory first reported a position in Janux Therapeutics in Q1 2024 and held it in 5 quarters.
Continuum Advisory's Janux Therapeutics position peaked at $2.81K in Q3 2024.
174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2025.

Based on Continuum Advisory's 13F filing for Q2 2025, filed 13 Aug 2025.